CINC · Cincor Pharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 |
|---|---|
| Revenue | - |
| Cost of Revenue | - |
| Gross Profit | - |
| R&D | $19.16M |
| SG&A | $1.96M |
| Total Operating Expenses | $21.13M |
| D&A | - |
| Operating Income | ($21.13M) |
| Interest Expense | - |
| Income Tax | - |
| Net Income | ($22.30M) |
| EPS - Basic | - |
| EPS - Diluted | - |
Balance Sheet
| Line item | FY 2021 |
|---|---|
| Cash & Equivalents | $11.48M |
| Accounts Receivable | - |
| Inventory | - |
| Accounts Payable | $3.67M |
| Current Assets | $26.80M |
| Total Assets | $26.80M |
| Current Liabilities | $6.89M |
| Long-term Debt | - |
| Total Liabilities | - |
| Stockholders' Equity | ($4.98M) |
| Retained Earnings | ($27.33M) |
Cash Flow
| Line item | FY 2021 |
|---|---|
| Operating Cash Flow | ($17.40M) |
| Investing Cash Flow | - |
| Financing Cash Flow | $31.99M |
| CapEx | - |
| Free Cash Flow | - |
Ratios
| Metric | FY 2021 |
|---|---|
| Profitability | |
| Gross margin | - |
| Operating margin | - |
| EBITDA margin | - |
| Net margin | - |
| Free cash flow margin | - |
| FCF / Net income | - |
| R&D / Revenue | - |
| SG&A / Revenue | - |
| Effective tax rate | - |
| Return on assets | -83.2% |
| Return on equity | 447.6% |
| Return on invested capital | - |
| Liquidity | |
| Current ratio | 3.89 |
| Quick ratio | 3.89 |
| Cash ratio | 1.67 |
| Leverage | |
| Debt / Equity | - |
| Debt / Assets | - |
| Debt / EBITDA | - |
| Interest coverage | - |
| Equity multiplier | -5.38 |
| Liabilities / Assets | - |
| Efficiency | |
| Asset turnover | - |
| Inventory turnover | - |
| Days sales outstanding | - |
| Days inventory outstanding | - |
| Days payable outstanding | - |
| Cash conversion cycle | - |
| Valuation | |
| P / E | - |
| P / B | - |
| P / S | - |
| EV / EBITDA | - |
| Growth | |
| Revenue growth (YoY) | - |
| Revenue CAGR (3y) | - |
| Revenue CAGR (5y) | - |
| Gross profit growth (YoY) | - |
| Operating income growth (YoY) | - |
| Net income growth (YoY) | - |
| EPS growth (YoY) | - |
| EPS CAGR (3y) | - |
| EPS CAGR (5y) | - |
| FCF growth (YoY) | - |
| FCF CAGR (5y) | - |
| Book value growth (YoY) | - |
Stability scores
Piotroski F-score
FY 2021 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- -ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- -Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CinCor Pharma against the 5 most active filers in the same SIC group.